Wim Goettsch from December 1, 2022, is a professor and chair for Health Technology Assessment (HTA) of Pharmaceuticals. His main objective is to ensure sustainable and affordable innovation of medicines. The primary goal of his research is to develop methods that support the implementation of new innovative medicines within the boundaries of our basic healthcare package, One of his topics of interest is to link the reimbursement of medicines to the outcomes of these treatments. Another area of interest is to make better use of data from clinical practice for the determination of the effectiveness and cost-effectiveness of medicines. He has a particular interest in medicines that are developed for small, heterogeneous patient groups. Finally, he is also very active in setting up the processes and methods to develop joint European assessments of new medicines and medical devices. In particular, he also focuses on how these methods and processes for joint European HTAs can efficiently be linked to the European process for Market Authorization and the development of national and European clinical guidelines.